Release Date: 03/06/14 10:01 Summary: Viralytics - Progress in CAVATAK Phase 2 Melanoma Trial Price Sensitive: Yes Download Document 86.5KB Download
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status